G. Giovannoni, G. Comi, S. Cook, K. Rammohan, P. Rieckmann et al., A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis, N Engl J Med, vol.362, pp.416-442, 2010.

T. P. Leist, G. Comi, B. Cree, P. K. Coyle, M. S. Freedman et al., Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial, Lancet Neurol, vol.13, issue.3, pp.257-67, 2014.

J. Pakpoor, G. Disanto, D. R. Altmann, S. Pavitt, B. P. Turner et al., No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine, Neurol Neuroimmunol Neuroinflamm, vol.2, issue.6, p.158, 2015.

C. Lebrun and F. Rocher, Cancer risk in patients with multiple sclerosis: potential impact of disease-modifying drugs, CNS Drugs, vol.378, issue.2, pp.169-182, 2018.

X. Moisset, M. Perié, B. Pereira, E. Dumont, C. Lebrun-frenay et al., Decreased prevalence of cancer in patients with multiple sclerosis: a casecontrol study, PLoS One, vol.12, issue.11, pp.188120-188131, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01650724

C. Lebrun, P. Vermersch, D. Brassat, G. Defer, L. Rumbach et al., Cancer and multiple sclerosis in the era of disease-modifying treatments, J Neurol, vol.258, issue.7, pp.1304-1315, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00996630

C. A. Girard, M. Lecacheur, B. Jouira, R. Berestjuk, I. Diazzi et al., A feedforward mechanosignaling loop confers resistance to therapies targeting the MAPK pathway in BRAFmutant melanoma, Cancer Res, vol.80, issue.10, pp.1927-1968, 2020.
URL : https://hal.archives-ouvertes.fr/inserm-02889519

G. Giovannoni, S. Sorensen, P. Cook, S. Rammohan, K. Rieckmann et al., Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study, Mult Scler, vol.24, issue.12, pp.1594-604, 2018.

S. Cook, T. Leist, G. Comi, X. Montalbán, G. Giovannoni et al., Safety of cladribine tablets in the treatment of patients with multiple sclerosis. An integrated analysis, Mult Scler Relat Dis, vol.29, pp.157-67, 2019.